Matthew R. Patterson
President and Chief Executive Officer
Mr. Patterson is the co-founder of Audentes Therapeutics and has served as president and CEO since the Company’s inception in November 2012. He has more than 20 years of experience in the research, development, and commercialization of innovative treatments for rare diseases and has held positions of senior management in both private and public biotechnology companies. Previously Mr. Patterson worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed, the world’s largest health-care dedicated investment firm.
Mr. Patterson is a member of the Board of Directors of Gilda's Club of New York City, which provides social and emotional support for people living with cancer. He also currently serves as Vice Chairman of the Alliance for Regenerative Medicine (ARM). Mr. Patterson received his B.A. in Biochemistry from Bowdoin College.
Senior Vice President, Chief Operating Officer
Ms. Holles has served as Senior Vice President and Chief Operating Officer since August 2015. Ms. Holles brings to this role over fifteen years of corporate development, strategic planning, and commercial experience gained in a range of therapeutic areas, with a focus in orphan diseases. Most recently, Ms. Holles served as Senior Vice President, Corporate Development at Hyperion Therapeutics, Inc. from 2013 through its acquisition by Horizon Pharma, plc in May 2015. From 2010-2013, Ms. Holles provided executive-level strategy and business development advisory services to a number of privately-held biopharmaceutical companies, most recently acting as Executive Vice President, Corporate Development at Immune Design, Inc. Earlier in her career, Ms. Holles served as Vice President, Business Development at KAI Pharmaceuticals, Inc. (acquired by Amgen in 2012) and previously held corporate development and commercial roles at InterMune, Inc. (acquired by Roche in 2014) and Genentech, Inc.
Ms. Holles holds an M.A. in molecular, cellular and developmental biology from the University of Colorado, Boulder, where she was a Howard Hughes Medical Institute Predoctoral Fellow, and an A.B. in Human Biology from Stanford University.
Senior Vice President, Chief Financial Officer
Mr. Soloway has served as Senior Vice President, Chief Financial Officer since October 2015, bringing over 20 years of experience in operations, corporate finance and venture capital in the life sciences industry. Prior to joining Audentes, Mr. Soloway served as the Senior Vice President, Chief Financial Officer of Ascendis Pharma A/S, a Danish biopharmaceutical company, where he helped lead a successful initial public offering on NASDAQ. Prior to Ascendis, Mr. Soloway co-founded Transcept Pharmaceuticals, Inc. At Transcept, Mr. Soloway held positions of increasing responsibility, serving initially as Senior Vice President, Operations and Chief Financial Officer and over time as Executive Vice President, Chief Operating Officer. In this role he oversaw project planning, manufacturing, pharmaceutical sciences, legal, human resources, regulatory and corporate communications. Prior to joining Transcept, Mr. Soloway financed and advised early stage healthcare and life sciences companies as a Principal at Montreux Equity Partners, a venture capital firm.
Mr. Soloway earned a B.S. in Entrepreneurial Studies from the University of Southern California and an M.B.A. from Georgetown University.
Suyash Prasad, M.D.
Senior Vice President and Chief Medical Officer
Dr. Prasad has served as Senior Vice President and Chief Medical Officer since February 2014. He has a wide range of experience and achievement in international drug development across Phase I to IV, with a specific focus in the clinical development of therapies to treat rare pediatric disorders. Dr. Prasad has worked in drug development for the past 14 years in positions of increasing responsibility at BioMarin Pharmaceutical, Inc., Genzyme Corporation, and Eli Lilly and Company. He has broad therapeutic expertise in neuromuscular disease, metabolic medicine, bone, neuroscience, endocrinology, immunology, and genetics. Dr. Prasad has significant experience with the development and commercialization of enzyme replacement therapies to treat lysosomal storage disorders, including Cerezyme®, Aldurazyme®, Fabrazyme®, and Myozyme®. For Pompe Disease, he led the global medical planning activities for Lumizyme® for the treatment of adult Pompe Disease and for Myozyme® to treat infantile Pompe. Most recently, he was responsible for the clinical development of novel treatments for phenylketonuria (PKU) and achondroplasia.
Dr. Prasad graduated in Medicine at the University of Newcastle-upon-Tyne, UK, where he received commendations for Pediatrics, Obstetrics and Gynecology, and Medical Ethics. He is a United Kingdom board certified physician with a sub-specialty interest in Pediatric Critical Care, and is a member of the Royal College of Physicians (MRCP) and the Royal College of Pediatrics and Child Health (MRCPCH). He received his Diploma in Pharmaceutical Medicine from the Royal College of Physicians of the United Kingdom, and has recently become an elected Fellow to the Faculty of Pharmaceutical Medicine (FFPM) and is a past recipient of the Outstanding Contribution Award from the Faculty of Pharmaceutical Medicine of the UK Royal College of Physicians. Dr. Prasad also currently sits on the board of the National PKU Association.
Senior Vice President, Regulatory Affairs
Ms. Newman joins Audentes with over 20 years of experience in regulatory affairs, and research and development, within the biotechnology industry. She joined Audentes after serving 7 years at SARcode Biotherapeutics Inc. (acquired by Shire Ltd.), most recently as Senior Vice President, Regulatory Affairs and Quality Assurance. Ms. Newman’s responsibilities included oversight of global regulatory strategic development, all primary regulatory agency interactions, and quality assurance for SARcode products. She previously held various management positions, with increasing responsibilities, in Regulatory Affairs at BioMarin Pharmaceutical, Inc., Berlex Inc. (now Bayer HealthCare Pharmaceuticals Inc.), and Sequus Pharmaceuticals, Inc. (now Johnson and Johnson). While at BioMarin, Ms. Newman oversaw the development and approval of Kuvan (sapropterin HCl) for the treatment of phenylketonuria (PKU), Naglazyme (galsulfase) for mucopolysaccharidosis (MPS) VI, and supported the final approval of Aldurazyme (laronidase) for MPS I. She has also held various leadership roles in research and development in oncology, neurology, and antifungal therapeutic areas.
Ms. Newman holds a B.S. in physiology from Oregon State University.
Senior Vice President, Human Resources & Corporate Affairs
Mr. Nagler has served as Senior Vice President, Human Resources and Corporate Affairs since February 2015. He has been in the life sciences industry for over 25 years, first as a leader in government affairs and later serving as a senior executive in human resources, along with corporate communications, legal affairs, and operations. Mr. Nagler joined Audentes having served the company as a human resources consultant. Prior to his consulting practice, Mr. Nagler spent nearly 10 years as Vice President Corporate Affairs and Secretary at ARYx Therapeutics, Inc. There he was responsible for human resources, public company compliance, legal, information technology, investor relations, and corporate communications. Prior to ARYx, Mr. Nagler served as Vice President Human Resources at Genentech, Inc., where he was responsible for a department with an annual $20 million budget that served an employee population of 7,600. During his tenure at Genentech, Mr. Nagler also served as Senior Director Government Affairs. Prior to joining Genentech, Mr. Nagler co-founded JLA Associates in Sacramento, a legislative consulting and association management company that he later sold to Nossaman, Guthner, Knox and Elliott, where he spent 10 years as a legislative advocate.
Mr. Nagler currently sits on the Planning Commission in the City of Pleasanton (California), having previously served as Chair of the Pleasanton Human Services Commission. He is a past member of the board of directors of U.C. Davis CONNECT, as well as the boards of the Northern California Chapter of the American Liver Foundation and the John Vasconcellos Legacy Project.
Mr. Nagler studied public policy and philosophy at the University of California Berkeley.
Senior Vice President, Research and Development
John Gray has served as Senior Vice President, Research and Development since December 2015 and prior to that was Vice President, Research and Development since July 2014. Dr. Gray has over 20 years of experience designing genetic therapies and vaccines, and developing manufacturing processes for those products. For 11 years prior to joining Audentes, Dr. Gray was the Director of Vector Production and Development at St. Jude Children’s Research Hospital where he led a team devoted to advancing the gene therapy vector science. In the area of lentiviral vector production, his team derived the GPRG stable cell line, the first such line to be used to successfully produce an HIV-based vector tested in a human clinical trial (for treatment of X-linked Severe Combined Immunodeficiency). He also contributed significantly to the Hemophilia B gene therapy project, for which he designed the self-complementary AAV Factor IX vector expression cassette and developed the production process used to manufacture the first two batches of clinical vector. During his tenure at St. Jude, Dr. Gray also worked on Chimeric Antigen Receptor modified cell therapy, lysosomal storage disorder gene therapy, and multiple hematopoietic stem/progenitor cell gene therapy projects.
Prior to joining St. Jude Children’s Research Hospital in 2003, Dr. Gray was a researcher in the laboratory of Dr. Richard Mulligan, where for 5 years he served as the Assistant Director of the Harvard Gene Therapy Initiative. Prior to this he worked for 5 years at Pfizer Animal Health designing bacterial and viral vectors for vaccine applications. Dr. Gray has a B.A. degree in Biochemistry from the University of California, Berkeley, and a Ph.D. degree in Biochemistry from the University of Colorado, Boulder.
Vice President, Corporate Development
Ms. Blessing has served as Vice President, Corporate Development since April 2014. She has 18 years of experience in biotechnology finance, business development, and alliance management. Over this period, Ms. Blessing has focused on programs for rare diseases and the application of genetic information to drug development. Before joining Audentes, Ms. Blessing served as Senior Director, Business Development and Alliance Management at 23andMe Inc., a personal genetics company. In her role at 23andMe, she led multiple genomic research programs with partners in the pharmaceutical industry. Prior to 23andMe, Ms. Blessing spent 8 years in Business and Corporate Development at BioMarin Pharmaceutical Inc., originating or leading successful licensing efforts in multiple therapeutic areas for rare diseases, including preclinical and clinical-stage products. Prior to her role in industry, Ms. Blessing was a Biotechnology Equity Research analyst at Cowen and Company LLC, UBS Securities LLC, and Needham and Company LLC.
Ms. Blessing earned a B.S. in Chemistry from the University of Richmond and a M.B.A. from Columbia Business School.
Vice President, Commercial Planning
Mr. Slocomb has served as Vice President, Commercial Planning since January 2015. He has over 22 years of experience in the areas of new product and portfolio planning, marketing, corporate development and venture capital in the biotechnology and pharmaceutical industries, including significant experience developing and executing commercialization strategies for biopharmaceuticals in rare diseases. Before joining Audentes, Mr. Slocomb was Senior Director, Corporate Development for Fate Therapeutics, which is developing stem cell therapies for rare hematologic and muscle disorders. Mr. Slocomb also spent over seven years at Amylin Pharmaceuticals, Inc. in new product commercialization leadership roles, including leading the creation and execution of the commercialization strategy for MYALEPT® (metreleptin for injection) for rare lipodystrophy.
Prior to his position at Amylin, Mr. Slocomb held roles of increasing responsibility in healthcare strategy consulting, strategic planning and marketing in the pharmaceutical industry and as the Principal of a healthcare venture capital fund.
Mr. Slocomb earned a B.A. in Genetics from the University of California, Berkeley and a M.B.A. from the Leonard N. Stern School of Business at New York University, where he was a Stern Scholar.
Barbara Wuebbels, RN
Vice President, Patient Advocacy
Ms. Wuebbels has served as Vice President Patient Advocacy since October 2013. She has more than 15 years of experience working with patients, patient organizations and clinicians in the rare disease community. Ms. Wuebbels joined Audentes following 6 years at BioMarin Pharmaceutical Inc. where she held positions of increasing responsibility in patient advocacy and medical affairs. This work included the creation of a global patient advocacy and investigator relations department. Through this new department, Ms. Wuebbels linked the critical perspectives of patient advocates with the internal planning of clinical and commercial activities. Earlier at BioMarin, she had oversight of BioMarin’s global registry for Maroteaux-Lamy Syndrome (MPS VI) patients. Prior to BioMarin, Ms. Wuebbels directed clinical education within the Orphan Drug Division at Medicis Pharmaceutical Corporation, and served as Director of Clinical Affairs at Vivra Health Advantage. Ms. Wuebbels started her career as a registered nurse.
Ms. Wuebbels earned a M.S. degree in Adult Health Nursing from Arizona State University, and a B.S. in Nursing from St. Louis University.